Kancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company’s strategic decision to focus on cardiovascular diseases.
Read MoreKancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145 Recardio’s phase III ready dutogliptin program and Kancera’s fractalkine program in phase II...
Read MoreThe period in brief – financial summary for the fourth quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 8,5 million (SEK 17,1 million). Operating loss for the quarter amounted to...
Read MoreThe period in brief – financial summary for the third quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 10,2 million (SEK 9,2 million). Operating loss for the quarter amounted to...
Read MoreDevelopment resources are focused on cardiovascular diseases, initially with focus on treatment of STEMI based on the positive phase IIa results in the FRACTAL-study. Extensive market access research concerning the preliminary product positioning in STEMI verifies that the opportunities...
Read MoreKancera AB (publ) today announces that Robert Edfors is appointed as Chief Medical Officer (CMO) at Kancera, effective on November 1, 2024. Robert Edfors, specialist in cardiology and internal medicine, has up until now been the company’s Chief Scientific...
Read MoreIn connection with the interim report for the second quarter 2024, Kancera AB (publ) today provides a general operational update concerning its clinical development program and reports that: the phase IIa part in the KANDOVA study has been initiated...
Read MoreThe period in brief – financial summary for the second quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 9,7 million (SEK 16,5 million). Operating loss for the quarter amounted to...
Read MoreKancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.
Read MoreKancera AB (publ) today reports that the first part, phase Ib, has been successfully completed in the ongoing KANDOVA study, a combined phase Ib/IIa study of Kancera’s candidate drug KAND567 in ovarian cancer in combination with carboplatin. The objective...
Read More